Article
Microbiology
Thamer A. Almangour, Leen Ghonem, Dareen Alassiri, Alanoud Aljurbua, Mohammed Al Musawa, Aminah Alharbi, Abdullah Almohaizeie, Sara Almuhisen, Jeelan Alghaith, Nader Damfu, Doaa Aljefri, Wafa Alfahad, Yaqoub Khormi, Menyfah Q. Alanazi, Yazed Saleh Alsowaida
Summary: This study aimed to compare the effectiveness and safety of C-T and CAZ-AVI in treating infections caused by resistant P. aeruginosa. The results showed no significant differences between C-T and CAZ-AVI in terms of in-hospital mortality, 30-day mortality, clinical cure, and safety. Both drugs can be potential options for the treatment of MDR P. aeruginosa infections.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Microbiology
Yiwei Zhu, Jie Chen, Han Shen, Zhongju Chen, Qi-Wen Yang, Jin Zhu, Xi Li, Qing Yang, Feng Zhao, Jingshu Ji, Heng Cai, Yue Li, Linghong Zhang, Sebastian Leptihn, Xiaoting Hua, Yunsong Yu
Summary: Klebsiella pneumoniae carbapenemase (KPC)-producing Pseudomonas aeruginosa (KPC-PA) strains were found in 40.4% of carbapenem-resistant P. aeruginosa (CRPA) isolates, with half of them resistant to ceftazidime-avibactam (CAZ-AVI). Eight plasmid types and two mobile genetic elements mediating bla(KPC-2) transmission were identified through sequencing. Curing bla(KPC-2) plasmids in 28 strains restored CAZ-AVI susceptibility, indicating its role in resistance.
Review
Infectious Diseases
Sisi Zhen, Hui Wang, Sizhou Feng
Summary: CAZ-AVI is a valuable therapeutic option for MDR-GNB infections, particularly for KPC or OXA-48 CRE infections. It shows significant benefits and improved clinical outcomes, even in immunocompromised patients. Early use of CAZ-AVI is associated with better efficacy. However, resistance development in CRE and MDR-PA against CAZ-AVI is a concern, and further investigations are needed.
Review
Infectious Diseases
Alessandro Mancuso, Luca Pipito, Raffaella Rubino, Salvatore Antonino Distefano, Donatella Mangione, Antonio Cascio
Summary: BJIs caused by multidrug-resistant gram-negative bacteria are becoming a concern. Ceftazidime-avibactam has shown efficacy and safety in treating osteomyelitis and prosthetic joint infections, despite not being approved for these indications. This study presents three successful cases of resistant Pseudomonas aeruginosa osteomyelitis treated with ceftazidime-avibactam alone or in combination therapy.
Article
Microbiology
Maria M. Montero, Sandra Domene Ochoa, Carla Lopez-Causape, Sonia Luque, Luisa Sorli, Nuria Campillo, Inmaculada Lopez Montesinos, Eduardo Padilla, Nuria Prim, Ariadna Angulo-Brunet, Santiago Grau, Antonio Oliver, Juan P. Horcajada
Summary: Ceftazidime-avibactam (CZA) has shown promise in treating Pseudomonas aeruginosa infections, particularly those that are extensively drug-resistant (XDR). Combination therapy with CZA and other antibiotics was more effective than monotherapy against XDR isolates, including those resistant to CZA. This study highlights the potential of CZA combinations in treating difficult-to-treat XDR P. aeruginosa infections.
MICROBIOLOGY SPECTRUM
(2021)
Article
Infectious Diseases
Laura Corbella, Jorge Boan, Rafael San-Juan, Mario Fernandez-Ruiz, Octavio Carretero, David Lora, Pilar Hernandez-Jimenez, Maria Ruiz-Ruigomez, Isabel Rodriguez-Goncer, Jose Tiago Silva, Francisco Lopez-Medrano, Manuel Lizasoain, Jennifer Villa, Jose Manuel Caro-Teller, Jose M. Aguado
Summary: Limited clinical experience suggests that ceftazidime-avibactam (CAZ-AVI) is a valid alternative for treating multidrug or extremely resistant Pseudomonas aeruginosa infections.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2022)
Article
Medicine, Research & Experimental
Aye Mya Sithu Shein, Dhammika Leshan Wannigama, Cameron Hurst, Peter N. Monk, Mohan Amarasiri, Vishnu Nayak Badavath, Phatthranit Phattharapornjaroen, William Graham Fox Ditcham, Puey Ounjai, Thammakorn Saethang, Naphat Chantaravisoot, Wanwara Thuptimdang, Sirirat Luk-in, Sumanee Nilgate, Ubolrat Rirerm, Chanikan Tanasatitchai, Naris Kueakulpattana, Matchima Laowansiri, Tingting Liao, Rosalyn Kupwiwat, Rojrit Rojanathanes, Natharin Ngamwongsatit, Arsa Thammahong, Hitoshi Ishikawa, Daniel Pletzer, Asada Leelahavanichkul, Naveen Kumar Devanga Ragupathi, Pattama Wapeesittipan, S. M. Ali Hosseini Rad, Talerngsak Kanjanabuch, Robin James Storer, Kazuhiko Miyanaga, Longzhu Cui, Hiroshi Hamamoto, Paul G. Higgins, Anthony Kicic, Tanittha Chatsuwan, Parichart Hongsing, Shuichi Abe
Summary: This study tested the efficacy of a combination therapy using phage and an adjuvant in treating multidrug-resistant Pseudomonas aeruginosa infections. The results showed that intranasal inhalation of phage along with CaEDTA successfully resensitized the bacteria to specific antibiotics, indicating its potential as a therapy for respiratory tract infections.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Immunology
Wei Yu, Luying Xiong, Qixia Luo, Yunbo Chen, Jinru Ji, Chaoqun Ying, Zhiying Liu, Yonghong Xiao
Summary: The study found that in vitro activity of aztreonam-avibactam was superior to ceftazidime-avibactam against carbapenem-resistant Escherichia coli and Klebsiella pneumoniae, while ceftazidime-avibactam showed better effect against carbapenem-resistant Pseudomonas aeruginosa.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Infectious Diseases
Juan Chen, Qiqiang Liang, Shuo Ding, Yongshan Xu, Yanting Hu, Jingyu Chen, Man Huang
Summary: This retrospective observational study evaluated the efficacy of ceftazidime-avibactam (CAZ/AVI) for treating carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection in lung transplant recipients. The study found that CAZ/AVI therapy showed good clinical and microbiological efficacy in this population, with high survival rates.
INFECTION AND DRUG RESISTANCE
(2023)
Article
Infectious Diseases
Inmaculada Lopez-Montesinos, Maria Milagro Montero, Sandra Domene-Ochoa, Carla Lopez-Causape, Daniel Echeverria, Luisa Sorli, Nuria Campillo, Sonia Luque, Eduardo Padilla, Nuria Prim, Santiago Grau, Antonio Oliver, Juan P. Horcajada
Summary: This study correlates the in vivo and in vitro findings of a patient with extensively drug-resistant P. aeruginosa infection, indicating a correlation between decreasing plasma levels of CAZ-AVI and the emergence of resistance. The study suggests that maintaining plasma CAZ-AVI levels at least 4 times the minimum inhibitory concentration (MIC) can prevent the development of resistance.
Article
Microbiology
C. Weber, T. Schultze, S. Goettig, J. Kessel, A. Schroeder, M. Tietgen, S. Besier, T. Burbach, S. Haeussler, T. A. Wichelhaus, D. Hack, V. A. J. Kempf, M. Hogardt
Summary: The study demonstrates that cefiderocol is the most effective antipseudomonal beta-lactam agent for multidrug-resistant (MDR) Pseudomonas aeruginosa, with susceptibility rates of 46.6%, 48.4%, and 97.3% for ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol, respectively. The most prevalent sequence type was ST235 (24.7%), followed by ST244, ST175, and ST233, all of which belong to the top 10 high-risk clones with worldwide distribution. Surveillance studies should pay special attention to MDR and highly virulent VIM- and ExoU-producing variants of ST235. Cefiderocol is the preferred treatment option for infections caused by carbapenemase-producing MDR P. aeruginosa, and it has shown favorable outcomes in complicated urinary tract infections and hospital-acquired pneumonia.
MICROBIOLOGY SPECTRUM
(2022)
Article
Infectious Diseases
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
Summary: This study aimed to investigate the susceptibility and β-lactamase-encoding genes of Pseudomonas aeruginosa isolates with discrepant resistance to different carbapenems. Data on P. aeruginosa isolates from 2012-2021 were analyzed, and minimum inhibitory concentrations were determined. β-lactamase-encoding genes were identified using multiplex polymerase chain reaction assays. The results showed that imipenem-resistant P. aeruginosa isolates had different susceptibility profiles and fewer carbapenemase genes compared to meropenem-resistant or doripenem-resistant isolates. Ceftazidime-avibactam and ceftolozane-tazobactam had higher susceptibility rates than meropenem-vaborbactam for meropenem-resistant P. aeruginosa. These findings are important for resistance trend monitoring and accurate antimicrobial treatment.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Immunology
Yixin Kang, Lu Xie, Jiyong Yang, Junchang Cui
Summary: This study evaluated the efficacy of ceftazidime-avibactam (CZA) and aztreonam-avibactam (AZA) against bloodstream infections (BSIs) or lower respiratory tract infections (LRTIs) caused by extensive drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa. The results showed that AZA can be used as a treatment option for infections caused by XDR/PDR P. aeruginosa producing IMP-45, VIM-1, or VIM-2. Optimized two-step-administration therapy (OTAT) with sufficient pharmacodynamic exposure may be the optimal treatment option for XDR/PDR P. aeruginosa with a high-level MIC of CZA/AZA.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Infectious Diseases
Alessandra Mularoni, Maria Lina Mezzatesta, Michele Pilato, Alice Annalisa Medaglia, Adriana Cervo, Dafne Bongiorno, Ausilia Aprile, Angelo Luca, Stefania Stefani, Paolo Grossi
Summary: A challenging case of metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis was successfully treated with surgical debridement and antibiotic therapy. Time-kill curves demonstrated strong synergistic effect of the triple antibiotic combination of ceftazidime/avibactam, aztreonam, and amikacin.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Microbiology
Pablo A. Fraile-Ribot, Javier Fernandez, Maria A. Gomis-Font, Lorena Forcelledo, Xavier Mulet, Carla Lopez-Causape, Antonio Oliver
Summary: The study investigated the mechanisms behind the in vivo switch in resistance phenotype of P. aeruginosa after ceftazidime-avibactam treatment. It was found that a single SNP difference can lead to a change in resistance profile, reverting a carbapenemase phenotype back into an ESBL phenotype. Through genetic analysis, it was discovered that certain mutations can alter the resistance patterns of bacteria in vivo.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)